FDA advisers vote ‘no’ on drug that may slow Alzheimer’s progression
By
Alicia Lasek
Nov 09, 2020
If approved by the FDA, aducanumab would be the first-ever drug marketed to slow progression of the brain-wasting disease, according to its developer. But an advisory committee was unconvinced of the drug’s...
Highly accurate Alzheimer’s blood test a ‘breakthrough,’ observers say
By
Alicia Lasek
Jul 30, 2020
The experimental blood test rivals the accuracy of standard diagnostic methods and may soon prove to be a cost-effective, accessible tool in the clinical setting, according to some in the scientific community.
Biogen seeks FDA approval for Alzheimer’s drug; aims to be first to slow disease
By
Alicia Lasek
Jul 09, 2020
Treatment with aducanumab reduced declines in memory, language, and activities of daily living performance, the drugmaker says.
Clinical Briefs for Friday, October 11
By
Alicia Lasek
Oct 10, 2019
Research sheds new light on how brain forms, recalls memories … FDA approves Dexcom G6 Pro continuous glucose monitor … Acute respiratory viral illness surveillance possible in long-term care: study...